Rhythm Pharmaceuticals
RYTM
88.45
-2.32
-2.56%
Rhythm Pharmaceuticals
US · RYTM
#1874 by market cap
Listed 2017
88.45
-2.32
-2.56%
Live - 5344 symbols - heartbeat 478s ago
· 2026-10-07 20:00
After-hours
88.45
0.00%
Overnight
88.34
-0.12%
- Market cap
- 6.09B
- P/E (TTM)i
- -28.35
- P/Bi
- 59.12
- EPSi
- -3.11
- Div yieldi
- 0.00%
- 52W posi
- 29%
Reader sentiment
Are you bullish or bearish on RYTM?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Financial Health how this is computed
Good
- Altman Z-Score is 13.42, above the 3.0 "safe zone" threshold.
- Most reliable for industrial/manufacturing companies; less meaningful for banks, insurers and other financials.
Revenue annual, last 8 years
Latest year +45.83% YoY
Margins
- Gross margin
- 89.73%
- Operating margin
- -101.19%
- Net margin
- -106.41%
Key ratios & quality
- Altman Z-Scorei
- 13.42
Altman Z-Score below ~1.8 suggests financial distress risk, above ~3.0 suggests low risk; the model is most reliable for industrial/manufacturing companies and less meaningful for banks and other financial firms.
Income statement
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Revenue | -- | 0 | 0 | 3.15M | 23.64M | 77.43M | 130.13M | 189.76M |
| Gross profit | -- | 0 | 0 | 2.56M | 21.51M | 68.13M | 116.76M | 170.27M |
| Selling & admin expenses | 28.08M | 36.55M | 46.13M | 68.49M | 92.03M | 117.53M | 144.30M | 194.94M |
| Research & development | 50.34M | 109.45M | 90.45M | 104.13M | 108.63M | 134.95M | 237.96M | 167.34M |
| Operating profit | -78.42M | -146.00M | -136.58M | -170.06M | -179.16M | -184.36M | -265.50M | -192.02M |
| Pretax profit | -74.06M | -140.73M | -134.00M | -69.61M | -181.12M | -184.11M | -260.26M | -196.04M |
| Tax | -- | -- | -- | 0 | 0 | 564.00K | 346.00K | 497.00K |
| Net profit | -74.06M | -140.73M | -134.00M | -69.61M | -181.12M | -184.68M | -260.60M | -196.54M |
| Basic EPS | -2 | -4 | -3 | -1 | -3 | -3 | -4 | -3 |
| Diluted EPS | -2.39 | -3.86 | -3.04 | -1.40 | -3.47 | -3.20 | -4.34 | -3.11 |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Revenue | 32.70M | 48.50M | 51.30M | 57.25M | 60.11M | 71.26M |
| Gross profit | 29.06M | 42.96M | 45.80M | 52.45M | 52.96M | 62.32M |
| Selling & admin expenses | 39.09M | 45.95M | 52.43M | 57.48M | 63.59M | 67.45M |
| Research & development | 36.97M | 42.31M | 46.03M | 42.03M | 41.73M | 43.43M |
| Operating profit | -47.00M | -45.30M | -52.65M | -47.06M | -52.36M | -48.55M |
| Pretax profit | -49.42M | -46.30M | -52.79M | -47.54M | -55.09M | -48.85M |
| Tax | 80.00K | 337.00K | 111.00K | -31.00K | 545.00K | 444.00K |
| Net profit | -49.50M | -46.63M | -52.90M | -47.51M | -55.64M | -49.30M |
| Basic EPS | -1 | -1 | -1 | -1 | -1 | -1 |
| Diluted EPS | -0.81 | -0.75 | -0.82 | -0.73 | -0.83 | -0.73 |
Balance sheet
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Total current assets | 258.69M | 302.40M | 181.67M | 308.39M | 354.24M | 308.27M | 374.20M | 466.92M |
| Cash & ST investments | 252.06M | 292.46M | 172.79M | 294.86M | 333.29M | 275.85M | 320.57M | 388.95M |
| Inventory | -- | -- | -- | 111.00K | 2.92M | 8.62M | 18.74M | 25.75M |
| Total assets | 260.21M | 308.52M | 187.07M | 329.52M | 382.48M | 332.75M | 392.27M | 480.20M |
| Total current liabilities | 13.58M | 24.42M | 17.99M | 43.43M | 39.81M | 55.20M | 115.52M | 105.94M |
| Short-term debt | -- | 472.00K | 535.00K | 606.00K | 684.00K | 770.00K | -- | 650.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- | -- | -- |
| Total liabilities | 13,954,000.00 | 27,503,000.00 | 20,545,000.00 | 45,372,000.00 | 118,219,000.00 | 162,986,000.00 | 227,724,000.00 | 210,170,000.00 |
| Total equity | 246.26M | 281.02M | 166.53M | 284.15M | 264.26M | 169.76M | 164.55M | 270.03M |
| Retained earnings | -184.60M | -325.33M | -459.33M | -528.94M | -710.06M | -894.74M | -1.16B | -1.35B |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Total current assets | 369.29M | 360.68M | 494.80M | 466.92M | 430.09M | 426.56M |
| Cash & ST investments | 314.49M | 291.03M | 416.05M | 388.95M | 340.63M | 330.90M |
| Inventory | 19.32M | 18.87M | 22.11M | 25.75M | 28.65M | 30.52M |
| Total assets | 386.69M | 372.73M | 506.87M | 480.20M | 442.32M | 437.27M |
| Total current liabilities | 111.82M | 129.46M | 104.27M | 105.94M | 103.20M | 123.59M |
| Short-term debt | 224.00K | 510.00K | 624.00K | 650.00K | 676.00K | 703.00K |
| Long-term debt | -- | -- | -- | -- | -- | -- |
| Total liabilities | 223,596,000.00 | 239,150,000.00 | 211,191,000.00 | 210,170,000.00 | 204,700,000.00 | 219,965,000.00 |
| Total equity | 163.09M | 133.58M | 295.68M | 270.03M | 237.62M | 217.30M |
| Retained earnings | -1.20B | -1.25B | -1.30B | -1.35B | -1.41B | -1.46B |
Cash flow
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -62.06M | -122.75M | -121.98M | -146.00M | -173.43M | -136.16M | -113.88M | -115.68M |
| Depreciation & amortization | 442.00K | 834.00K | 690.00K | 1.16M | 1.67M | 1.76M | 1.56M | 1.34M |
| Free cash flow | -62.78M | -126.14M | -122.19M | -151.44M | -177.71M | -136.20M | -113.88M | -116.63M |
| Dividends paid | -- | -- | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 162.88M | 161.35M | 0 | 161.73M | 131.11M | 48.88M | 39.15M | 222.69M |
| Ending cash balance | 49.94M | 62.70M | 101.26M | 59.58M | 128.01M | 60.41M | 89.60M | 54.82M |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| Operating cash flow | -40.35M | -23.31M | -26.62M | -25.39M | -44.19M | -9.15M |
| Depreciation & amortization | 383.00K | 379.00K | 304.00K | 272.00K | 252.00K | 251.00K |
| Free cash flow | -40.35M | -23.31M | -26.62M | -26.34M | -44.19M | -9.15M |
| Dividends paid | -- | -- | -- | -- | -- | -- |
| Stock buybacks / issuance | 34.03M | 0 | 188.66M | 2.00K | 0 | 0 |
| Ending cash balance | 106.56M | 136.11M | 52.75M | 54.82M | 62.74M | 66.22M |
Returns & efficiency
| Line item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|
| ROE %i | -37.88 | -53.38 | -59.88 | -30.89 | -66.05 | -85.10 | -276.33 | -251.14 |
| ROA %i | -35.96 | -49.49 | -54.07 | -26.95 | -50.88 | -51.64 | -72.98 | -46.29 |
| ROIC %i | -40.11 | -54.64 | -60.14 | -30.71 | -65.09 | -84.50 | -265.34 | -233.49 |
| 5-year avg ROE %i | -- | -- | -- | -49.82 | -49.62 | -59.06 | -103.65 | -141.90 |
| EBIT margin %i | -- | -- | -- | -5,391.85 | -744.22 | -219.85 | -184.17 | -92.47 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Current ratioi | 19.05 | 12.38 | 10.10 | 7.10 | 8.90 | 5.58 | 3.24 | 4.41 |
| Quick ratioi | 18.56 | 11.98 | 9.60 | 6.81 | 8.53 | 5.27 | 2.94 | 3.92 |
| Debt / assetsi | 0.00 | 1.15 | 1.65 | 0.77 | 0.51 | 0.38 | 1.00 | 0.83 |
| LT debt / equityi | -- | 1.10 | 1.53 | 0.68 | 0.48 | 0.29 | 18.12 | 2.40 |
| Interest coveragei | -- | -- | -- | -- | -33.82 | -12.25 | -11.63 | -8.52 |
| Revenue CAGR (3Y) %i | 0.00 | 0.00 | 0.00 | -- | -- | -- | 245.54 | 100.23 |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- | -- | -- |
| Line item | 2025-03 | 2025-06 | 2025-09 | 2025-12 | 2026-03 | 2026-06 |
|---|---|---|---|---|---|---|
| ROE %i | -432.20 | -1,373.71 | -247.09 | -251.14 | -293.04 | -461.65 |
| ROA %i | -53.93 | -49.95 | -45.43 | -46.29 | -50.14 | -51.91 |
| ROIC %i | -395.29 | -1,009.52 | -227.96 | -233.49 | -273.93 | -420.92 |
| 5-year avg ROE %i | -- | -- | -- | -- | -- | -- |
| EBIT margin %i | -107.66 | -102.79 | -97.79 | -92.47 | -83.79 | -77.44 |
| FCF / sales %i | -- | -- | -- | -- | -- | -- |
| Current ratioi | 3.30 | 2.79 | 4.75 | 4.41 | 4.17 | 3.45 |
| Quick ratioi | 2.97 | 2.45 | 4.31 | 3.92 | 3.63 | 3.00 |
| Debt / assetsi | 1.05 | 1.12 | 0.82 | 0.83 | 0.87 | 0.84 |
| LT debt / equityi | 20.26 | -- | 2.36 | 2.40 | 2.57 | 2.89 |
| Interest coveragei | -6.93 | -7.15 | -7.96 | -8.52 | -9.21 | -10.05 |
| Revenue CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| Net income CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
| FCF CAGR (3Y) %i | -- | -- | -- | -- | -- | -- |
Revenue breakdown most recent period
Business
Development and commercialization of therapies for patients with rare diseases100.00%
Quote time 2026-10-07 20:00:08 · For reference only, not investment advice and not tailored to your situation.